Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-α.

Genomic-Based High Throughput Screening Identifies Small
Molecules That Differentially Inhibit the Antiviral and
Immunomodulatory Effects of IFN-α
Bo Chen,1* Qin Zong,2* Ricardo Cibotti,1* Chad Morris,1 Juana Castaneda,2 Brian Naiman,1 Derong Liu,2
Anna Glodek,2 Gary P Sims,1 Ronald Herbst,1 Stephen K Horrigan,2 Peter A Kiener,1 Dan Soppet,2
Anthony J Coyle,1 and Laurent Audoly1
1

Respiratory, Inflammation and Autoimmunity Department, MedImmune Inc., Gaithersburg, Maryland, United States of America;
Avalon Pharmaceuticals Inc., Germantown, Germantown, Maryland, United States of America

2

Multiple lines of evidence suggest that inhibition of Type I Interferons, including IFN-α, may provide a therapeutic benefit for autoimmune diseases. Using a chemical genomics approach integrated with cellular and in vivo assays, we screened a small compound library to identify modulators of IFN-α biological effects. A genomic fingerprint was developed from both ex vivo patient genomic information and in vitro gene modulation from IFN-α cell-based stimulation. A high throughput genomic-based screen then was applied to prioritize 268 small molecule inhibitors targeting 41 different intracellular signaling pathways. Active compounds were profiled further for their ability to inhibit the activation and differentiation of human monocytes using disease-related stimuli. Inhibitors targeting NF-κB or Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling emerged as “dissociated inhibitors” because they did not modulate IFN-α anti-viral effects against HSV-1 but potently inhibited other immune-related functions. This work describes a novel strategy to identify small molecule inhibitors for the treatment of autoimmune disorders.
Online address: http://www.molmed.org doi: 10.2119/2008-00028.Chen

INTRODUCTION
Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disorder that is characterized by anti-nuclear

References: 1. Boumpas DT et al. (1995) Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal (1987) Interferons and their actions. Annu. Rev. 3. Pestka S, Krause CD, and Walter MR. (2004) Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202:8–32. 5. Darnell JE Jr, Kerr IM, and Stark GR. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular 6. Platanias LC. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling 7. Pascual V, Farkas L, and Banchereau J. (2006) Systemic lupus erythematosus: all roads lead to type I interferons 8. Kirou KA et al. (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic (2004) The emerging role of interferon in human systemic lupus erythematosus 10. Crow MK, Kirou KA, and Wohlgemuth J. (2003) Microarray analysis of interferon-regulated genes 12. Baechler EC et al. (2003) Interferon-inducible gene expression signature in peripheral blood 13. Ytterberg SR and Schnitzer TJ. (1982) Serum interferon levels in patients with systemic lupus erythematosus 14. Ronnblom L and Alm GV. (2003) Systemic lupus erythematosus and the type I interferon system. 16. Santiago-Raber ML et al. (2003) Type-I interferon receptor deficiency reduces lupus-like disease in 17. Banchereau J and Pascual V. (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases 18. Bol D and Ebner R. (2006) Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform 19. Stoughton RB and Friend SH. (2005) How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug. Discov. 4:345–50. 20. Hieronymus H et al. (2006) Gene expression signature-based chemical genomic prediction 21. Lamb J et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease 22. Wei G et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of 23. Feng X et al. (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with 24. Hua J, Kirou K, Lee C, and Crow MK. (2006) Functional assay of type I interferon in systemic (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus (2000) Serum levels of IFN-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus 27. Svane IM et al. (2006) Characterization of monocyte-derived dendritic cells maturated 29. Harle P et al. (2001) Expression of human and macaque type I IFN- transgenes interferes with 30. Nguyen KB et al. (2002) Critical role for STAT4 activation by type 1 interferons in the interferongamma response to viral infection 31. Rothfuchs AG et al. (2006) STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by